b
r
c
human
rhinoviru
lower
respiratori
tract
infect
lrti
associ
mortal
hematopoiet
cell
transplant
hct
howev
risk
factor
lrti
well
character
sought
develop
risk
score
progress
lrti
upper
respiratori
tract
infect
urti
hct
recipi
risk
factor
lrti
within
day
analyz
use
cox
regress
among
hct
recipi
rhinoviru
urti
januari
march
final
multivari
model
includ
factor
meaning
effect
bootstrap
optim
correct
concord
statist
weight
score
contribut
base
hazard
ratio
determin
cumul
incid
curv
estim
probabl
lrti
variou
score
cutoff
rhinoviru
urti
event
progress
lrti
final
multivari
model
allogen
graft
prior
rhinoviru
urti
low
lymphocyt
count
low
albumin
posit
cytomegaloviru
serostatu
recipi
statin
use
steroid
use
mgkgday
associ
progress
lrti
weight
risk
score
cutoff
highest
sensit
specif
determin
risk
score
cutoff
associ
progress
lrti
cumul
incid
versu
cutoff
p
weight
risk
score
progress
rhinoviru
lrti
help
identifi
stratifi
patient
clinic
manag
futur
clinic
trial
therapeut
hct
recipi
human
rhinoviru
hrv
commonli
detect
respiratori
viru
hematopoiet
cell
transplant
hct
upper
lower
respiratori
tract
although
rare
virolog
confirm
lower
respiratori
tract
infect
lrti
develop
mortal
rate
due
hrv
appear
high
even
similar
seen
respiratori
virus
includ
influenza
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
risk
factor
associ
lrti
popul
defin
rsv
piv
influenza
human
metapneumoviru
hmpv
includ
lymphopenia
use
steroid
condit
regimen
done
systemat
hct
recipi
present
hrv
upper
respiratori
tract
infect
urti
studi
hrv
infect
includ
hct
recipi
patient
hematolog
malign
factor
like
present
patient
lrti
includ
inpati
statu
lymphopenia
hypoalbuminemia
note
case
lrti
virolog
confirm
studi
analysi
conduct
manner
furthermor
sever
key
factor
includ
viral
load
evalu
studi
present
studi
aim
identifi
specif
risk
factor
progress
lrti
cohort
patient
present
urti
develop
risk
score
diseas
progress
help
clinician
risk
stratifi
patient
may
benefit
intens
monitor
followup
ultim
identif
patient
import
clinic
trial
design
requir
defin
enrich
cohort
high
risk
lrti
may
benefit
potenti
intervent
research
center
subject
elig
inclus
studi
posit
hrv
upper
respiratori
tract
posttranspl
patient
hrv
infect
transplant
exclud
clinic
data
collect
databas
supplement
review
medic
record
studi
approv
institut
review
board
fred
hutchinson
cancer
research
center
subject
sign
inform
consent
permit
use
data
research
respiratori
tract
sampl
collect
part
routin
clinic
care
adult
pediatr
patient
respiratori
symptom
test
respiratori
virus
realtim
reversetranscriptas
pcr
rtqpcr
assay
includ
rsv
hmpv
influenza
virus
b
piv
adenoviru
human
coronavirus
hrv
human
bocaviru
rtqpcr
multiplex
panel
perform
respiratori
sampl
time
period
studi
rtqpcr
cycl
threshold
ct
use
proxi
viral
load
lower
ct
indic
higher
viral
load
ct
valu
analyz
quartil
well
median
urti
defin
posit
hrv
pcr
result
upper
tract
sampl
nasopharyng
swab
wash
symptomat
patient
without
radiograph
abnorm
lrti
defin
posit
lower
tract
sampl
bronchoalveolar
lavag
bal
lung
biopsi
autopsi
specimen
without
radiograph
abnorm
proven
probabl
lrti
respect
posit
upper
tract
sampl
radiograph
abnorm
possibl
lrti
chest
xray
chest
comput
tomographi
result
includ
complet
within
week
last
posit
hrv
date
lower
tract
sampl
result
includ
month
urti
date
day
lrti
diagnosi
defin
date
hrv
detect
lower
tract
specimen
provenprob
lrti
date
radiograph
abnorm
detect
possibl
lrti
patient
met
criteria
lrti
within
day
urti
consid
lrti
present
includ
progress
analys
hrv
ill
event
consid
new
event
week
elaps
posit
sampl
neg
hrv
sampl
hrv
posit
sampl
probabl
progress
upper
lower
hrv
infect
estim
use
cumul
incid
treat
death
compet
risk
event
factor
associ
progress
lrti
evalu
use
cox
regress
model
follow
variabl
consid
potenti
predictor
progress
patient
age
sex
donor
type
cell
sourc
year
transplant
perform
condit
regimen
recent
wbc
count
neutrophil
lymphocyt
monocyt
platelet
count
hrv
infect
within
week
lowest
albumin
level
week
hrv
infect
highest
daili
steroid
dose
week
hrv
infect
pretranspl
lung
function
hctspecif
comorbid
index
hctci
time
transplant
hrv
infect
hrv
ct
valu
acut
chronic
graftversushostdiseas
recipi
donor
cytomegaloviru
cmv
serostatu
recipi
donor
statin
use
defin
previous
report
covari
p
univari
analys
candid
inclus
multivari
cox
regress
model
initi
variabl
retain
multivari
model
p
full
model
multivari
model
reduc
construct
risk
score
evalu
chang
bootstrap
optim
correct
concord
statist
cstatist
factor
remov
full
model
bootstrap
cstatist
base
replic
factor
littl
impact
cstatist
remov
score
point
contribut
develop
use
hazard
ratio
final
multivari
model
hazard
ratio
round
nearest
integ
scale
maximum
achiev
score
risk
score
subject
calcul
base
covari
valu
associ
point
given
curv
construct
examin
impact
shift
cut
point
risk
score
sensit
specif
rate
cumul
incid
curv
progress
lrti
score
valu
posit
predict
valu
neg
predict
valu
seri
binari
cutoff
valu
well
within
categor
rang
score
evalu
compar
use
logrank
test
gray
test
subject
miss
valu
albumin
cmv
serostatu
recipi
statin
statu
exclud
univari
multivari
analys
statist
signific
defin
p
sa
version
sa
institut
inc
cari
nc
r
version
use
statist
analys
among
patient
undergo
hct
studi
time
period
posit
hrv
least
respiratori
site
figur
result
hrv
ill
event
event
repres
urti
present
wherea
event
involv
present
lrti
urti
event
event
complet
data
covari
includ
progress
analys
among
subject
multipl
hrv
urti
event
median
time
event
day
interquartil
rang
iqr
subject
urti
present
median
age
year
iqr
slight
male
predomin
tabl
seventeen
percent
urti
event
progress
lrti
proven
lrti
event
possibl
lrti
event
probabl
lrti
event
occur
hrv
urti
event
occur
recipi
allogen
hct
event
progress
lrti
group
proven
lrti
event
possibl
lrti
event
median
time
progress
urti
lrti
day
event
iqr
day
allogen
subject
iqr
figur
b
subject
possibl
lrti
event
none
bal
perform
univari
analysi
event
donor
type
condit
regimen
prior
hrv
event
steroid
use
albumin
level
recipi
statin
use
recipi
cmv
serostatu
recent
wbc
count
neutrophil
lymphocyt
monocyt
count
suffici
associ
progress
lrti
consid
inclus
multivari
model
tabl
notabl
presenc
viral
copathogen
pulmonari
function
intraven
immunoglobulin
hrv
ct
valu
upper
tract
sampl
associ
progress
lrti
univari
multipl
multivari
model
risk
factor
progress
proven
lrti
shown
supplementari
tabl
candid
variabl
univari
analysi
evalu
multivari
model
covari
ad
sequenti
cstatist
calcul
model
optim
model
highest
cstatist
achiev
tabl
final
model
cstatist
wherea
optim
correct
cstatist
risk
score
develop
describ
weight
contribut
factor
shown
tabl
specif
sensit
score
develop
lrti
entir
cohort
allogen
cohort
shown
figur
b
respect
among
subject
score
cutoff
highest
sensit
specif
correspond
posit
predict
valu
neg
predict
valu
popul
cumul
incid
curv
progress
lrti
subject
stratifi
rang
binari
score
shown
figur
b
repres
posit
neg
predict
valu
given
respect
cumul
incid
progress
lrti
group
versu
group
logrank
gray
test
p
figur
illustr
abil
score
stratifi
popul
mutual
exclus
level
risk
cumul
incid
progress
lrti
follow
score
logrank
test
gray
test
p
weight
risk
score
appli
allogen
subgroup
cumul
incid
curv
shown
figur
score
cumul
incid
versu
score
logrank
test
gray
test
p
score
also
appli
whole
cohort
evalu
proven
lrti
outcom
figur
show
cumul
incid
curv
progress
proven
lrti
score
cumul
incid
versu
score
logrank
test
gray
test
p
larg
retrospect
studi
hct
recipi
infect
hrv
upper
respiratori
tract
establish
risk
factor
develop
risk
score
progress
lrti
knowledg
largest
statist
rigor
studi
systemat
examin
patient
specif
present
urti
determin
risk
subsequ
lrti
multivari
model
lrti
event
subject
signific
risk
factor
identifi
includ
allogen
transplant
prior
hrv
urti
event
lymphocyt
count
cellsl
recipi
statin
use
recipi
cmv
serostatu
steroid
use
mgkgday
character
risk
factor
progress
calcul
chang
bootstrap
optim
correct
cstatist
risk
factor
develop
optim
model
risk
predict
use
model
develop
weight
score
describ
perform
characterist
score
variou
risk
score
present
articl
novel
tool
potenti
help
risk
stratifi
patient
clinic
care
futur
clinic
trial
hrv
recent
recogn
signific
pathogen
caus
sever
diseas
poor
outcom
certain
high
risk
group
includ
infant
pregnant
women
asthmat
hospit
adult
immunocompromis
children
adult
hrv
lrti
develop
hct
recipi
mortal
rate
compar
associ
rsv
influenza
piv
studi
hrv
infect
includ
hct
recipi
patient
hematolog
malign
factor
like
present
patient
lrti
includ
inpati
statu
lymphopenia
hypoalbuminemia
hct
recipi
alon
center
hypoalbuminemia
isol
respiratori
copathogen
associ
lrti
multivari
model
analys
although
done
timedepend
manner
similar
find
present
studi
lymphopenia
hypoalbuminemia
associ
progress
lrti
evalu
copathogen
upper
respiratori
tract
risk
factor
find
associ
lrti
lymphopenia
associ
progress
lrti
respiratori
virus
includ
piv
rsv
hmpv
influenza
also
common
hrv
lrti
subject
prior
studi
monocytopenia
evalu
systemat
prior
respiratori
viru
progress
studi
although
trend
toward
signific
hmpv
monocytopenia
associ
mortal
hct
recipi
hrv
rsv
lrti
rel
role
monocyt
lymphocyt
progress
diseas
understood
studi
evalu
cell
type
concurr
potenti
mechan
inflammatori
immun
modul
via
hrv
induc
monocyt
cell
direct
ifng
releas
plausibl
steroid
use
well
describ
risk
factor
progress
lrti
mani
respiratori
virus
higher
dose
mgkgday
associ
hrv
lrti
present
studi
note
steroid
longer
frequent
use
diseas
treatment
institut
reflect
low
frequenc
use
cohort
howev
even
lower
dose
steroid
mgkgday
show
trend
toward
signific
multivari
model
includ
weight
score
center
may
higher
rate
steroid
use
still
abl
appli
score
patient
popul
prior
posttranspl
hrv
urti
infect
associ
increas
risk
lrti
interest
somewhat
unexpect
find
suggest
effect
cumul
burden
hrv
infect
perhap
mediat
inflammatori
respons
increas
likelihood
lrti
develop
parainfluenza
virus
urti
without
lrti
associ
late
airflow
declin
similar
pathway
may
play
hrv
infect
although
possibl
overestim
new
event
definit
week
event
chosen
given
recent
surveil
data
show
median
durat
hrv
shed
hct
recipi
day
rang
given
long
durat
event
present
studi
median
day
iqr
believ
captur
prolong
viral
shed
rather
truli
new
viral
event
recipi
cmv
serostatu
associ
increas
risk
lrti
novel
find
respiratori
viru
diseas
sever
cmv
profound
impact
immun
system
immunocompet
immunosuppress
individu
known
immunosuppress
effect
well
known
affect
nonrelaps
mortal
hct
patient
cmv
also
shown
increas
risk
virus
hct
howev
mechan
poorli
understood
cmv
associ
progress
studi
plausibl
result
valid
differ
cohort
studi
need
elucid
mechan
recipi
statin
use
risk
factor
hrv
lrti
also
intrigu
find
corrobor
prior
result
separ
cohort
center
demonstr
trend
toward
associ
recipi
statin
use
respiratori
viral
infect
lrti
statin
may
act
immunosuppress
via
direct
inhibit
induct
mhcii
express
ifng
thu
lead
reduc
cell
activ
may
also
effect
type
ifn
receptor
signal
monocyt
set
hrv
challeng
lead
reduc
inflammatori
respons
role
statin
hrv
progress
valid
cohort
evalu
respiratori
viru
infect
independ
evalu
impact
hrv
viral
load
found
associ
progress
lrti
ct
valu
surrog
viral
load
limit
given
divers
hrv
genotyp
result
differ
amplif
effici
use
rtqpcr
assay
consensu
hrv
primer
probe
set
rt
digit
pcr
recent
shown
provid
precis
quantif
howev
even
evalu
extrem
highest
viral
load
group
ct
valu
lowest
percentil
effect
seen
lung
transplant
recipi
higher
hrv
viral
load
associ
increas
symptom
associ
lrti
immunocompet
pediatr
patient
viral
load
associ
diseas
sever
older
younger
children
also
associ
higher
rate
viremia
oxygen
use
variabl
role
viral
load
studi
date
suggest
limit
captur
accur
viral
load
clinic
sampl
done
studi
host
factor
includ
immun
respons
may
import
player
progress
lrti
clinic
outcom
addit
hrv
speci
evalu
present
studi
data
suggest
hrvc
may
associ
wors
outcom
especi
children
presenc
viral
upper
respiratori
tract
associ
progress
hrv
lrti
provid
clinic
applic
find
develop
weight
risk
score
progress
lrti
use
methodolog
allow
multipl
sampl
within
dataset
develop
optim
model
final
model
show
accept
robust
cstatist
use
model
develop
weight
score
show
specif
sensit
calcul
rang
score
well
cumul
incid
curv
stratifi
score
within
mutual
exclus
score
rang
maximum
sensit
specif
demonstr
score
howev
optim
score
depend
ultim
applic
score
exampl
risk
score
use
patient
risk
stratif
intervent
clinic
trial
score
higher
sensit
neg
predict
valu
may
desir
sampl
size
limit
abil
extens
evalu
proven
lrti
respiratori
virus
rsv
piv
associ
wors
clinic
outcom
sever
separ
multivari
model
howev
risk
factor
progress
proven
lrti
similar
low
albumin
low
monocyt
count
steroid
appli
risk
score
proven
lrti
outcom
subject
risk
score
higher
associ
proven
lrti
larger
sampl
size
separ
risk
score
proven
lrti
could
develop
although
like
risk
factor
would
remain
similar
probabl
lrti
could
repres
contamin
cumul
incid
curv
progress
lrti
subject
stratifi
b
rang
binari
score
cutoff
repres
posit
neg
predict
valu
given
cutoff
respect
logrank
gray
test
compar
versu
group
p
cumul
incid
curv
progress
lrti
subject
stratifi
mutual
exclus
level
risk
c
logrank
test
gray
test
p
upper
respiratori
tract
bal
procedur
howev
case
probabl
lrti
cohort
although
analys
use
accept
resampl
methodolog
bootstrap
ultim
multicent
studi
need
valid
score
especi
given
differ
clinic
practic
includ
use
steroid
immunodefici
score
index
develop
allogen
hct
recipi
rsv
infect
predict
lrti
rsv
associ
mortal
score
also
appli
influenza
similar
variabl
evalu
present
studi
associ
outcom
except
steroid
use
suggest
rhinoviru
progress
may
determin
uniqu
set
risk
factor
compar
respiratori
virus
separ
risk
score
need
studi
strength
limit
first
retrospect
studi
data
collect
includ
viral
load
determin
depend
clinic
databas
howev
institut
data
transplant
recipi
prospect
record
central
databas
also
conduct
detail
chart
review
everi
patient
obtain
addit
clinic
data
second
captur
proven
lrti
hrv
detect
lower
respiratori
tract
abnorm
imag
figur
cumul
incid
curv
progress
lrti
allogen
recipi
progress
proven
lrti
subject
b
stratifi
score
logrank
test
gray
test
p
curv
possibl
lrti
hrv
detect
upper
respiratori
tract
abnorm
imag
lower
tract
sampl
institut
use
bal
base
standard
protocol
outlin
bal
perform
hct
recipi
respiratori
viru
detect
upper
respiratori
tract
abnorm
chest
imag
howev
ultim
need
bal
determin
attend
physician
thu
proven
probabl
case
hrv
detect
lower
respiratori
tract
without
abnorm
imag
may
miss
includ
proven
possibl
lrti
event
probabl
event
occur
effect
mitig
howev
proven
lrti
may
relev
outcom
given
mortal
rate
seen
proven
hrv
lrti
differ
outcom
observ
proven
lrti
piv
rsv
regardless
mani
institut
routin
use
bal
virolog
confirm
thu
result
lrti
event
broadli
applic
final
data
includ
allogen
autolog
hct
recipi
may
bia
toward
increas
test
allogen
group
therefor
lrti
event
captur
howev
risk
score
perform
reason
well
allogen
subgroup
abl
evalu
risk
factor
hrv
lrti
case
without
lower
respiratori
tract
separ
prior
studi
presenc
associ
mortal
hct
recipi
proven
hrv
lrti
suggest
hrv
detect
lower
tract
pathogen
regardless
therefor
make
proven
hrv
lrti
import
endpoint
bal
done
possibl
lrti
case
plausibl
pathogen
contribut
radiograph
chang
thu
true
lrti
event
howev
state
clinic
practic
bal
often
attempt
data
avail
yet
patient
consid
lrti
thu
includ
possibl
lrti
endpoint
sever
epidemiolog
studi
clinic
trial
respiratori
virus
hct
recipi
use
definit
lrti
includ
possibl
case
summari
describ
risk
factor
develop
risk
score
progress
lrti
larg
cohort
hct
recipi
hrv
urti
risk
score
propos
may
implic
risk
stratifi
patient
intens
clinic
monitor
addit
risk
stratif
help
inform
design
futur
random
clinic
trial
novel
therapeut
includ
grow
field
viru
specif
cell
current
evalu
respiratori
virus
includ
piv
hmpv
